Clinical trials: Prostate Disease
Prostate Cancer
Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)
This study will look to see if the combination of ridaforolimus and bicalutamide works better than placebo and bicalutamide in men with prostate cancer.
- Trial name
- NCT00777959
- Testing
- ridaforolimus (MK8669), open-label ridaforolimus (MK8669)
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Benign Prostatic Hyperplasia
Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH
The purpose of this study is to evaluate the safety and efficacy of a single treatment of PRX302 for the treatment of Benign Prostatic Hyperplasia (BPH) as compared to placebo.
- Trial name
- PLUS-1 (NCT01966614)
- Testing
- PRX302
- Where
- 76 sites in United States, Australia and 4 more
- Volunteers
- 479 people
- Sponsor
- Sophiris Bio Corp
Prostate Cancer
Focal ExAblate MR-Guided Focused Ultrasound Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer
This study is intended to show that ExAblate™ MRgFUS is a safe procedure that can significantly postpone or eliminate the need of patients with organ confined intermediate risk prostate cancer to undergo a definitive treatment…
- Trial name
- NCT02968784
- Testing
- ExAblate MRgFUS
- Where
- 4 sites in Canada, China and 1 more
- Volunteers
- 53 people
- Sponsor
- InSightec
Prostatic Neoplasms
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
The primary objective in this study is to evaluate bone scan response at Week 24 based on the quantified technetium-99 bone scan lesion area (BSLA).
- Trial name
- NCT02034552
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Abiraterone acetate, Prednisone
- Where
- 19 sites in United States
- Volunteers
- 68 people
- Sponsor
- Bayer
Metastatic Castration-resistant Prostatic Neoplasms
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in…
- Trial name
- KLK2-comPAS (NCT07164443)
- Testing
- Pasritamig, Best Supportive Care (BSC), JNJ-87189401
- Where
- 174 sites in United States, Australia and 15 more
- Volunteers
- 1,203 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Cancer
Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)
This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten…
- Trial name
- UROCOR (NCT01284608)
- Where
- 33 sites in Spain
- Volunteers
- 197 people
- Sponsor
- AstraZeneca
Solid Tumors, Cancer
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
This is a Phase 2 study to evaluate the efficacy and safety of cabozantinib (XL184) in subjects with selected advanced tumor types.
- Trial name
- NCT00940225
- Testing
- Cabozantinib
- Where
- 47 sites in United States, Belgium and 3 more
- Volunteers
- 730 people
- Sponsor
- Exelixis
Prostate Cancer
A Study of Pertuzumab in Participants With Prostate Cancer
This study will evaluate the efficacy and safety of intravenous (IV) pertuzumab in participants with hormone-refractory prostate cancer who have had no previous chemotherapy.
- Trial name
- NCT02480010
- Testing
- Pertuzumab
- Where
- 11 sites in France, Germany and 4 more
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Cancer, Breast Cancer
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05311618
- Testing
- NGM438, Pembrolizumab (KEYTRUDA ®)
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Prostate Cancer
PASCUAL (Prostate Assay Specific Clinical Utility at Launch) Study
The main hypothesis of this study is to demonstrate that the use of the ConfirmMDx for Prostate Cancer test in previously biopsied patients improves urologists' patient management by reducing unnecessary repeat biopsies…
- Trial name
- PASCUAL (NCT02250313)
- Where
- 15 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- MDx Health
Urinary Tract Infections, Prostatitis
Rapid Molecular Organism Identification and Mixed Flora Antibiotic Resistance Profiling (MixAR) Prospective Study
In this protocol, investigators are examining the ability for a novel multiplex PCR assay with mixed floral antibiotic resistance profiling is safe and increases effective treatment for urinary tract infections in a urology…
- Conditions
- Urinary Tract Infections, Prostatitis, Interstitial Cystitis
- Trial name
- RapIDMixAR (NCT03931538)
- Testing
- Guidance 4.0 PCR test, Urine Culture
- Where
- United States
- Volunteers
- 2,511 people
- Sponsor
- Pathnostics
Prostate Cancer
A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer
This is the first study of MLN2704 administered to humans. The purpose of the study is to determine the highest dose of MLN2704 that can be given safely to patients with prostate cancer, and to identify any side effects…
- Trial name
- NCT00052000
- Testing
- MLN2704 (DM1 conjugated monoclonal antibody MLN591)
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostate Cancer
SpaceOAR System Pivotal Study
Evaluate the safety of the SpaceOAR System when the hydrogel is injected between the rectum and prostate in men undergoing radiation therapy (IG-IMRT)
- Trial name
- NCT01538628
- Testing
- SpaceOAR System
- Where
- 20 sites in United States
- Volunteers
- 222 people
- Sponsor
- Boston Scientific Corporation
Prostate Cancer
A Study of Leuprolide to Treat Prostate Cancer
To assess the efficacy and safety of 2 new formulations of leuprolide acetate 45 mg 6-month depot, Formulation A or Formulation B, for the treatment of patients with prostate cancer.
- Trial name
- NCT00626431
- Testing
- Leuprolide acetate - Formulation A, Leuprolide acetate - Formulation B
- Where
- 63 sites in United States
- Volunteers
- 310 people
- Sponsor
- Abbott
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
The purpose of this study is to describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received either…
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00950911
- Testing
- amg 162
- Where
- 17 sites in Czechia, United Kingdom
- Volunteers
- 35 people
- Sponsor
- Amgen
Prostate Cancer
A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer
A Phase Ib2, multicenter, randomized, double-blind, placebo-controlled safety and efficacy study evaluating different regimens of the immunotherapeutic drug, Mobilan (M-VM3), in patients with prostate cancer.
- Trial name
- NCT02844699
- Testing
- Mobilan (M-VM3)
- Where
- 4 sites in Russia
- Volunteers
- 24 people
- Sponsor
- Panacela Labs LLC
Prostate Cancer
A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.
- Trial name
- NCT00036543
- Testing
- Atrasentan
- Where
- 232 sites in United States, Australia and 16 more
- Volunteers
- 1,000 people
- Sponsor
- Abbott
Prostatic Neoplasms
Second Primary Cancers in Patients With Castration Resistant Prostate Cancer
This study aims at estimating the incidence of second primary malignancies as well as the overall survival among metastasized prostate cancer (mPC) and metastasized castrate-resistant prostate cancer (mCRPC) patients not treated…
- Trial name
- BOCARP (NCT02702908)
- Where
- Germany
- Volunteers
- 6,442 people
- Sponsor
- Bayer
Prostatic Neoplasms, Prostatic Hyperplasia
Prostate Mechanical Imager (PMI) Clinical Bridging Study
The purpose of this study is to evaluate an imaging capability Prostate Mechanical Imager (PMI), a PC-based device utilizing a transrectal probe with pressure sensor arrays and motion tracking system, aimed at providing composite…
- Trial name
- PMI (NCT00822952)
- Where
- 5 sites in United States
- Volunteers
- 71 people
- Sponsor
- Artann Laboratories
Cancer of Prostate, Cancer of the Prostate
Sipuleucel-T Manufacturing Demonstration Study
To demonstrate that sipuleucel-T can be successfully manufactured for subjects with metastatic castrate resistant prostate cancer (mCRPC) at a European manufacturing facility.
- Conditions
- Cancer of Prostate, Cancer of the Prostate, Neoplasms, Prostate, Neoplasms, Prostatic
- Trial name
- NCT01477749
- Testing
- sipuleucel-T
- Where
- 4 sites in Austria, France and 2 more
- Volunteers
- 47 people
- Sponsor
- Dendreon
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.